July 24, 2014: Gilead's earnings report will be closely watched on both Wall Street and Capitol Hill, where the argument about how much the world’s second-most-valuable biotech company should charge for its new $84,000 hepatitis C drug Sovaldi is getting more and more heated.
July 24, 2014: Brand-name drug makers are being accused of hiding behind a mandated safety program (Risk Evaluation and Mitigation Strategies) to thwart aspiring generic rivals.
July 24, 2014: The director of a U.S. government bioterror lab that potentially exposed scores of workers to live anthrax last month has resigned, the U.S. Centers for Disease Control and Prevention.
July 23, 2014: Galena BioPharma CEO Mark Ahn continues to shell out big money for obsolete, rarely prescribed drug products. Tuesday, Galena entered into a license agreement with MonoSol Rx for Zuplenz.